A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Latest Information Update: 01 Oct 2024
At a glance
- Drugs AZD 0486 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Amgen; AstraZeneca; TeneoBio
- 31 Jul 2024 Planned number of patients changed from 206 to 116.
- 09 May 2024 Planned number of patients changed from 116 to 206.
- 09 May 2024 Planned End Date changed from 22 Jan 2027 to 15 Jan 2027.